2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
2
Active Trials
200 recruiting
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Molecure S.A. (previously OncoArendi S.A.) is a company with 2 orphan drug designations across 3 rare diseases. Active clinical trials in 2 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| idiopathic pulmonary fibrosis | 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | Des.TrialAppr. |
| ovarian cancer | - | Des.TrialAppr. |
| sarcoidosis | 5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
13
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio